HIV感染者合并癌症使用免疫检查点抑制剂的安全性与活性:CATCH-IT国际联盟真实世界报告
本回顾性研究纳入390例接受抗PD-1或抗PD-L1治疗的晚期癌症HIV感染者,评估安全性与疗效。20%发生任何级别免疫相关不良事件,7.7%发生≥3级。在匹配的转移性非小细胞肺癌队列中,HIV感染者与非HIV感染者的安全性和疗效相似。
要点
- 390例HIV感染者中,20%发生任何级别irAE,7.7%发生≥3级irAE。
- 客观缓解率因癌种而异:非黑色素瘤皮肤癌69%、NSCLC 31%、HCC 16%、HNSCC 11%。
- 匹配的mNSCLC队列中,PWH与PWOH的PFS和OS无显著差异。
核心结论
- 在HIV感染者中,免疫检查点抑制剂在不同癌种间显示出差异活性,且无超额毒性。
- 在匹配的转移性非小细胞肺癌HIV感染者与非HIV感染者队列中,免疫检查点抑制剂的安全性和活性相似。
研究设计与样本
- 回顾性研究,纳入390例接受抗PD-1或抗PD-L1为基础治疗的晚期癌症HIV感染者。
- 采用Kaplan-Meier法估计总生存期和无进展生存期,客观缓解率按RECIST 1.1或其他肿瘤特异性标准评估。
- 采用限制性平均生存时间比较匹配的转移性非小细胞肺癌HIV感染者与非HIV感染者的OS和PFS。
主要发现
- 390例HIV感染者中,中位年龄58岁,85%(331例)为男性,36%(138例)为黑人,70%(274例)接受抗PD-1/抗PD-L1单药治疗。
- 最常见癌种为非小细胞肺癌(28%,111例)、肝细胞癌(11%,44例)和头颈部鳞状细胞癌(10%,39例)。
- 70%(152/216)CD4+ T细胞计数≥200 cells/µL,94%(179/190)HIV病毒载量<400 copies/mL。
- 20%(79/390)发生任何级别免疫相关不良事件,7.7%(30/390)发生≥3级免疫相关不良事件。
- 客观缓解率:非黑色素瘤皮肤癌69%、非小细胞肺癌31%、肝细胞癌16%、头颈部鳞状细胞癌11%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer. METHODS: This retrospective study included PWH treated with anti-PD-1- or anti-PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC). RESULTS: Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti-PD-1/anti-PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts ≥200 cells/µL, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade ≥3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH v 110 PWOH), 20% (12/61) PWH and 22% (24/110) PWOH had irAEs. Adjusted 42-month RMST difference was -0.06 months (95% CI, -5.49 to 5.37; P = .98) for PFS and 2.23 months (95% CI, -4.02 to 8.48; P = .48) for OS. CONCLUSION: Among PWH, ICIs demonstrated differential activity across cancer types with no excess toxicity. Safety and activity of ICIs were similar between matched cohorts of PWH and PWOH with mNSCLC.
引用
- El Zarif T, Nassar AH, Adib E, et al. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium. J Clin Oncol. 2023. PMID: 37192435. doi:10.1200/JCO.22.02459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。